Literature DB >> 19622361

Increased mortality risk in patients with phenotypic hereditary hemochromatosis but not in their first-degree relatives.

Maria Elmberg1, Rolf Hultcrantz, Fereshte Ebrahim, Sigvard Olsson, Stefan Lindgren, Lars Lööf, Per Stål, Sven Wallerstedt, Sven Almer, Hanna Sandberg-Gertzén, Anders Ekbom, Johan Askling.   

Abstract

BACKGROUND & AIMS: Hereditary hemochromatosis (HH) is an autosomal-recessive disorder characterized by iron overload. Relatives of HH patients were screened and those with HH-associated mutations and an increased iron load were identified. However, little is known about their mortality or strategies for their management. We assessed mortality among Swedish patients with HH and their first-degree relatives using health and census registers.
METHODS: We performed a matched population-based cohort study of 3832 patients with HH and their 14,496 first-degree relatives using data collected from 1990 through 2007. Mortality data from these groups were compared with that of 38,969 population controls and their 143,349 first-degree relatives using Cox regression analyses.
RESULTS: Patients identified on the basis of hospitalization with HH had an increased risk (relative risk [RR]) for death (RR, 2.45; 95% confidence interval [CI], 2.27-2.64; 857 deaths). Patients identified through other means had a mortality risk that was lower than those identified in the hospital but higher than controls (RR, 1.15; 95% CI, 1.00-1.33; 216 deaths). Their first-degree relatives had only a marginally increased mortality risk (RR, 1.05; 95% CI, 1.01-1.10); this RR was similar to that of patients' spouses (RR, 1.09; 95% CI, 0.86-1.38; 82 deaths). Patients with HH who also had a family history of HH did not have an increased mortality risk compared with other groups (RR, 1.05; 95% CI, 0.67-1.62; 21 deaths).
CONCLUSIONS: Patients with HH have a modestly increased mortality risk compared with controls. The mortality of relatives is increased marginally compared with controls, and is similar among biological and nonbiological relatives.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19622361     DOI: 10.1053/j.gastro.2009.07.038

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  8 in total

1.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Orthopade       Date:  2010-06       Impact factor: 1.087

Review 2.  [Osteoarthritis in hereditary metabolic diseases].

Authors:  J Zwerina; T Dallos
Journal:  Z Rheumatol       Date:  2010-05       Impact factor: 1.372

Review 3.  [Hemochromatosis].

Authors:  B Oppl; J Zwerina
Journal:  Z Rheumatol       Date:  2015-09       Impact factor: 1.372

4.  Does hemochromatosis predispose to celiac disease? A study of 29,096 celiac disease patients.

Authors:  Jonas F Ludvigsson; Joseph A Murray; Paul C Adams; Maria Elmberg
Journal:  Scand J Gastroenterol       Date:  2012-12-20       Impact factor: 2.423

5.  External review and validation of the Swedish national inpatient register.

Authors:  Jonas F Ludvigsson; Eva Andersson; Anders Ekbom; Maria Feychting; Jeong-Lim Kim; Christina Reuterwall; Mona Heurgren; Petra Otterblad Olausson
Journal:  BMC Public Health       Date:  2011-06-09       Impact factor: 3.295

6.  Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model.

Authors:  Barbara de Graaff; Lei Si; Amanda L Neil; Kwang Chien Yee; Kristy Sanderson; Lyle C Gurrin; Andrew J Palmer
Journal:  Pharmacoecon Open       Date:  2017-03

7.  EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

Authors:  Graça Porto; Pierre Brissot; Dorine W Swinkels; Heinz Zoller; Outi Kamarainen; Simon Patton; Isabel Alonso; Michael Morris; Steve Keeney
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

8.  Mesenchymal iron deposition is associated with adverse long-term outcome in non-alcoholic fatty liver disease.

Authors:  Sebastian K Eder; Alexandra Feldman; Georg Strebinger; Jana Kemnitz; Stephan Zandanell; David Niederseer; Michael Strasser; Heike Haufe; Karl Sotlar; Felix Stickel; Bernhard Paulweber; Christian Datz; Elmar Aigner
Journal:  Liver Int       Date:  2020-05-28       Impact factor: 5.828

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.